Vimarsana
Biggest News Aggregation in the World

Page 10 - Briggs Morrison News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Briggs Morrison. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Briggs Morrison Today - Breaking & Trending Today

Calamos Advisors LLC Makes New Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Vimarsana News

Calamos Advisors LLC Makes New Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Calamos Advisors LLC acquired a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 12,937 shares of the company’s stock, valued at approximately $329,000. Several other large investors have […]

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $33.57 Average Price Target from Brokerages - Vimarsana News

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $33.57 Average Price Target from Brokerages

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) have received a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1 year target price […]

Carisma Therapeutics Closes Merger with Sesen Bio - Vimarsana News

Carisma Therapeutics Closes Merger with Sesen Bio

/PRNewswire/ -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, and...

Photys Therapeutics Debuts with $75 Million Series A Funding to Advance New Class of Bifunctional Mo - Vimarsana News

Photys Therapeutics Debuts with $75 Million Series A Funding to Advance New Class of Bifunctional Mo

- Phosphorylation-inducing chimeric small molecules (PHICS) are a new class of bifunctional medicines that direct and repair aberrant and dysfunctional proteins- PHICS enable precise phosphorylation, an important post-translational modification that controls protein function, including activation, stabilization, tra...

Photys Therapeutics Raises $75M in Series A Funding - Vimarsana News

Photys Therapeutics Raises $75M in Series A Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!